(Page 2 of 2)
roughly 50 percent, from $2.75 a share to about $1.40. The company plans to continue development despite the setback.
—San Diego’s Ocera Therapeutics said it won approval from European regulators to market its treatment for diarrhea-predominant irritable bowel syndrome. The private company, which specializes in gastrointestinal and liver diseases, said it has opened discussions with potential partners to provide sales and marketing in the European Union and certain other countries for its spherical carbon adsorbent, Zysa.
San Diego-based Obalon Therapeutics, which has been developing a “gastric space occupying device” for treating obesity, has raised a $16.5 million equity round, according to a recent regulatory filing. The company has not disclosed much information about its technology, however, and appears to have no website.
—Vista, CA-based Aperio Technologies, which has developed a digital pathology information system along with technology for scanning microscope slides into the system, has raised $5.5 million of a planned $6 million in debt and rights to acquire securities, according to a recent regulatory filing. Aperio has raised more than $47 million altogether, according to VentureWire.
—Carlsbad. CA-based Ivera Medical, which won a new FDA clearance in January for a disinfecting device designed to reduce hospital-acquired catheter-related bloodstream infections, has raised $1.2 million of a planned $2.5 million from investors, according to a regulatory filing.
—San Diego-based Topera, which has developed mapping systems that help identify the electrical source of irregular heart beats, has raised $2.75 million from investors, according to a recent regulatory filing. In its filing, the company shortened its name from Topera Medical. Last year Topera raised a small, undisclosed amount in a Series A funding round from a group of individual investors.